Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
240 participants
OBSERVATIONAL
2022-04-16
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Gender-affirming Hormone Therapy on Transgender People
NCT06022562
Sex Hormone Overdose and Misuse in Chinese Transgender and Gender Non-conforming Population
NCT05583058
Transition in Transgender
NCT04736797
Fertility Desires and Reproductive Needs of Transgender People
NCT03836027
Sexuality in Transmen During Hormone and Operative Treatment
NCT03637920
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
transgender men
People whose sex assigned at birth is female but whose self-identified gender is male.
GAHT for transgender men
Testosterone undecanoate
transgender women
People whose sex assigned at birth is male but whose self-identified gender is female.
GAHT for transgender women
Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Healthy cisgender people
People whose sex assigned at birth corresponds with their self-identified gender.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GAHT for transgender men
Testosterone undecanoate
GAHT for transgender women
Estradiol and antiandrogens (Spironolactone or Cyproterone acetate)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria
* Aged between 18 to 40 years
* People desire to start the GAHT
* No previous history of gender-affirming interventions
* Having full ability to make informed consent
* Dextromanual
Exclusion Criteria
* Who has fertility demand but have not made fertility preservation
* With contradictions of GAHT
* Comorbid diseases are not under control
* Alcohol or drug abuse
* Hormonal and chromosomal disorders
* History of gender affirming surgery
* Current psychiatric disorders
* History of brain trauma or neurological pathologies
* Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics)
* Claustrophobia
* Implanted metal and medical devices (pacemakers, ceramic teeth, etc.),
* Tattoos or eyebrow tattooing (heavy metal dye)
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tsinghua University
OTHER
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hong Tianpei
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tianpei Hong, PhD., M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Endocrinology and Metabolism, Peking University Third Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University Third Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CGAHT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.